We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva's (TEVA) Pain Drug Vantrela ER Receives FDA Approval
Read MoreHide Full Article
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) announced that the FDA has approved Vantrela ER for the treatment of pain which is severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Teva’s share price has declined 45% in the past one year, compared with the Zacks classified Medical-Generics Drugs industry’s fall of 33%.
Vantrela, which is an extended-release formulation of hydrocodone bitartrate, has been developed utilizing the company’s proprietary abuse deterrence technology. As expected, Vantrela’s label carries a description regarding the product’s abuse-deterrent properties that are likely to reduce, but not fully prevent abuse of the drug, when the tablets are manipulated. The label also contains a Boxed Warning that includes addiction, abuse and misuse, which can lead to overdose and even death, as well as serious or fatal respiratory depression.
Last year in August , another pharma giant Pfizer Inc. (PFE - Free Report) received FDA approval for Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride), for oral use, CII, for the management of severe pain on regular basis, around-the-clock, long-term opioid treatment and for which alternative treatment options are insufficient.
Anika’s earnings estimates for 2016 and 2017 were up 3.9% and 0.5%, respectively, in the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, the average being 33.14%. Its share price was up 35.6% in the past one year.
Enzo Biochem’s loss estimates for 2017 narrowed 5.88% over the past 60 days. The company recorded a positive earnings surprise in three of the last four quarters, the average being 22.50%. Its share price was up 49% in the past one year.
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Teva's (TEVA) Pain Drug Vantrela ER Receives FDA Approval
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) announced that the FDA has approved Vantrela ER for the treatment of pain which is severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Teva’s share price has declined 45% in the past one year, compared with the Zacks classified Medical-Generics Drugs industry’s fall of 33%.
Vantrela, which is an extended-release formulation of hydrocodone bitartrate, has been developed utilizing the company’s proprietary abuse deterrence technology. As expected, Vantrela’s label carries a description regarding the product’s abuse-deterrent properties that are likely to reduce, but not fully prevent abuse of the drug, when the tablets are manipulated. The label also contains a Boxed Warning that includes addiction, abuse and misuse, which can lead to overdose and even death, as well as serious or fatal respiratory depression.
Last year in August , another pharma giant Pfizer Inc. (PFE - Free Report) received FDA approval for Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride), for oral use, CII, for the management of severe pain on regular basis, around-the-clock, long-term opioid treatment and for which alternative treatment options are insufficient.
Zacks Rank & Key Picks
Teva currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the health care sector include Anika Therapeutics Inc. (ANIK - Free Report) and Enzo Biochem, Inc. (ENZ - Free Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Anika’s earnings estimates for 2016 and 2017 were up 3.9% and 0.5%, respectively, in the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, the average being 33.14%. Its share price was up 35.6% in the past one year.
Enzo Biochem’s loss estimates for 2017 narrowed 5.88% over the past 60 days. The company recorded a positive earnings surprise in three of the last four quarters, the average being 22.50%. Its share price was up 49% in the past one year.
TEVA PHARM ADR Price
TEVA PHARM ADR Price | TEVA PHARM ADR Quote
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>